Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel™
02 déc. 2021 09h30 HE
|
Vivos Inc.
Richland WA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), on November 30 Vivos Inc met with the Food and Drug Administration to obtain suggestions on improving the current draft of...
TripleBlind Lands $24 Million in Series A Funding Led by General Catalyst and Mayo Clinic, in an Oversubscribed Round
18 oct. 2021 13h00 HE
|
TripleBlind
Enables Enterprises to Unlock and Commercialize enormous amount of Unused Data*Mayo Clinic Joins Round as Strategic Investor, Expands Equity PositionAccenture and Mayo Add Board Observers KANSAS...
Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
11 juin 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical...
TripleBlind Receives Investment from Mayo Clinic, Expanding Current Collaboration
27 avr. 2021 09h00 HE
|
TripleBlind
KANSAS CITY, Mo., April 27, 2021 (GLOBE NEWSWIRE) -- Today, TripleBlind announced that it expanded its collaboration with Mayo Clinic, which invested in a seed extension round, the only investor...
Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
08 févr. 2021 15h21 HE
|
Sorrento Therapeutics, Inc.
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple...
TripleBlind Collaborates with Mayo Clinic on Next Generation Algorithm Sharing and Training on Encrypted Data
15 déc. 2020 09h00 HE
|
TripleBlind
KANSAS CITY, Mo., Dec. 15, 2020 (GLOBE NEWSWIRE) -- TripleBlind announced today it is collaborating with Mayo Clinic researchers who will use TripleBlind tools to validate interoperability of...
Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse Spleen Injections Demonstrating Uniform Perfusion and Stability
09 déc. 2020 09h30 HE
|
Vivos Inc.
Richland WA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the...
Sorrento Secures Exclusive License From Mayo Clinic for Antibody-Drug-Nanoparticle Albumin-Bound Immune Complex (ADNIC) Platform
14 sept. 2020 06h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has entered into an exclusive license agreement with Mayo Clinic for a...
PETVIVO HOLDINGS, INC. HIRES DR. DAVID B MASTERS AS DIRECTOR OF SCIENCE AND TECHNOLOGY
10 sept. 2020 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, Sept. 10, 2020 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for...
Gentex Announces Smart Lighting Technology For Medical Applications
07 janv. 2020 11h00 HE
|
Gentex Corporation
LAS VEGAS, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Today at CES, Gentex Corporation (NASDAQ: GNTX) unveiled an innovative lighting technology for medical applications that was co-developed with Mayo...